CoVigi phase IV multicentric trial evaluating COVID-19
vaccination adverse events and immune response dynamics in
cancer patients: First results on antibody and cellular
immunity

a 2021

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity

OBERMANNOVA, R., Regina DEMLOVÁ, I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA et. al.

Základní údaje

Originální název

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity

Autoři

OBERMANNOVA, R., Regina DEMLOVÁ (203 Česká republika, garant, domácí), I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA, Marie MLNAŘÍKOVÁ (203 Česká republika), Kateřina PILÁTOVÁ (203 Česká republika), Jiří NEVRLKA (203 Česká republika), Hana LEJDAROVÁ (203 Česká republika), B. WEINBERGEROVA, Z. CERMAKOVA, Dalibor VALÍK (203 Česká republika), Jiří MAYER (203 Česká republika), Igor KISS (203 Česká republika) a Lenka ZDRAŽILOVÁ DUBSKÁ (203 Česká republika)

Vydání

Congress of the European Society for Medical Oncology ESMO 2021, 2021

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

CoViGi

Impakt faktor

Impact factor: 51.769

Kód RIV

RIV/00216224:14110/21:00123104

Organizační jednotka

Lékařská fakulta

ISSN

DOI

http://dx.doi.org/10.1016/j.annonc.2021.08.1556

UT WoS

000700527703109

Klíčová slova česky

SARS-CoV-2; klinické hodnocení; vakcíny; Pfizer-BioNTech; AstraZeneca; Johnson&Johnson; Moderna; nežádoucí účinky

Klíčová slova anglicky

SARS-CoV-2; clinical trial; vaccines; Pfizer-BioNTech; AstraZeneca; Johnson & Johnson; Modern; adverse events

Štítky

FN Brno, MOÚ, MU, operator, RIV

Změněno: 20. 10. 2023 13:50, Mgr. Tereza Miškechová

Anotace

V originále

SARS-CoV-2 infection may be a threat for those undergoing active anti-cancer therapy. We aim to study adverse events, efficacy, and immune response in Covid-19 vaccinated patients focusing on possibly interfering therapy.

Návaznosti

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

OBERMANNOVA, R., Regina DEMLOVÁ, I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA, Marie MLNAŘÍKOVÁ, Kateřina PILÁTOVÁ, Jiří NEVRLKA, Hana LEJDAROVÁ, B. WEINBERGEROVA, Z. CERMAKOVA, Dalibor VALÍK, Jiří MAYER, Igor KISS a Lenka ZDRAŽILOVÁ DUBSKÁ. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity. In Congress of the European Society for Medical Oncology ESMO 2021. 2021. ISSN 0923-7534. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2021.08.1556.

@proceedings{1807081,
   author = {Obermannova, R. and Demlová, Regina and Selingerova, I. and Doubek, M. and Okrouhlicova, D. and Mlnaříková, Marie and Pilátová, Kateřina and Nevrlka, Jiří and Lejdarová, Hana and Weinbergerova, B. and Cermakova, Z. and Valík, Dalibor and Mayer, Jiří and Kiss, Igor and Zdražilová Dubská, Lenka},
   booktitle = {Congress of the European Society for Medical Oncology ESMO 2021},
   doi = {http://dx.doi.org/10.1016/j.annonc.2021.08.1556},
   keywords = {SARS-CoV-2; clinical trial; vaccines; Pfizer-BioNTech; AstraZeneca; Johnson & Johnson; Modern; adverse events},
   language = {eng},
   note = {CoVigi},
   title = {CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity},
   url = {https://www.annalsofoncology.org/article/S0923-7534(21)03785-6/fulltext},
   year = {2021}
}

TY  - CONF
ID  - 1807081
AU  - Obermannova, R. - Demlová, Regina - Selingerova, I. - Doubek, M. - Okrouhlicova, D. - Mlnaříková, Marie - Pilátová, Kateřina - Nevrlka, Jiří - Lejdarová, Hana - Weinbergerova, B. - Cermakova, Z. - Valík, Dalibor - Mayer, Jiří - Kiss, Igor - Zdražilová Dubská, Lenka
PY  - 2021
TI  - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
N1  - CoVigi
KW  - SARS-CoV-2
KW  - clinical trial
KW  - vaccines
KW  - Pfizer-BioNTech
KW  - AstraZeneca
KW  - Johnson & Johnson
KW  - Modern
KW  - adverse events
UR  - https://www.annalsofoncology.org/article/S0923-7534(21)03785-6/fulltext
N2  - SARS-CoV-2 infection may be a threat for those undergoing active anti-cancer therapy. We aim to study adverse events, efficacy, and immune response in Covid-19 vaccinated patients focusing on possibly interfering therapy.
ER  -

OBERMANNOVA, R., Regina DEMLOVÁ, I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA, Marie MLNAŘÍKOVÁ, Kateřina PILÁTOVÁ, Jiří NEVRLKA, Hana LEJDAROVÁ, B. WEINBERGEROVA, Z. CERMAKOVA, Dalibor VALÍK, Jiří MAYER, Igor KISS a Lenka ZDRAŽILOVÁ DUBSKÁ. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity. In \textit{Congress of the European Society for Medical Oncology ESMO 2021}. 2021. ISSN~0923-7534. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2021.08.1556.

Podrobný výpis o publikaci